Dr. Qian-fei Wang is currently a professor and principal investigator at Beijing Institute of Genomics (BIG), Chinese Academy of Sciences (CAS). Dr. Wang received his Ph.D. from Johns Hopkins University School of Medicine, and pursued his postdoctoral training in the Genomics Division at Lawrence Berkeley National Laboratory, University of California, Berkeley. He was awarded the National Science Fund for Distinguished Young Scholars in 2014. His lab has employed a combined genomic and functional characterization strategy to: 1) explore the functional and clinical relevance of newly discovered genomic aberrations in acute leukemia; 2) identify key genes/pathways critical for drug resistance in chemotherapy; 3) define genomic signatures for the classification of responders in AML drug treatment. Research work from Dr. Wang’s lab was published in journals such as Nature Genetics, Blood, PNAS, and Leukemia. These studies may lead to improved treatment strategy and better outcome in AML patients.

Research Areas

Hematology and Cancer Genomics


PhD     2002     Johns Hopkins University, Baltimore, MD,USA           Cellular and Molecular Medicine

Bachelor        1993     Shandong Medical University, Jinan, P. R. China           Clinical Medicine


Work Experience

2009/7- Professor, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

2007-2009     Research Associate (Assistant Professor), University of Chicago, Chicago, IL

2002-2006  Genomics Division, University of California, Berkeley/Lawrence Berkeley National Laboratory,Berkeley, CA   

1995-1997  Visiting Scholar in Clinical Immunology, Johns Hopkins University, Baltimore, MD

1993-1995   Research fellow, Beijing Institute of Geriatrics, Beijing,China



1. Zhang P, Xing CH, Rhodes SD, He YZ, Deng K, Li ZM, He FH, Zhu CY, Nguyen L, Zhou Y, Chen S,Mohammad K S,

 Guise TA, Abdel-Wahab O, Xu MJ, Wang QF* and Yang FC*. Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice. Stem Cell Reports.6(6),914-925,2016

2. Kang L*, Wu J, Tao Y, Li HL, Liu XL, Gao SR* and Wang QF*.Cell type-specific expression profile and signaling requirements in early hematopoietic reprogramming. Stem Cells Dev. 24(12),1483-1492,2015

3. Chen A, Yang J, Hu S* and Wang QF*. The priming inducton regimen of HAG as a low dose  strategy in AML clonal evolution. Sci China Life Sci.58(12),1302-1305,2015 

4. Wang QF* and Cheng T*. Evidences for mutations in the histone modifying gene SETD2 as critical drivers in leukemia development. Sci China Life Sci. 57(9):944-946,2014

5. Cai J, Miao XX, Li YY, Smith C, Tsang K, Cheng LZ* and Wang QF*. Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells. Stem Cell Reports. 3(2):227-233,2014 

6. Zhu XF, He FH, Zeng HM, Ling SP, Chen AL, Wang YQ, Yan XM, Wei W, Pang YK, Cheng H, Hua CL, Zhang Y, Yang XJ, Lu X, Cao LH , Hao LT, Dong LL, Zou W, Wu J, Li X, Zheng S, Yan J, Zhou J, Zhang LX , Mi SL, Wang XJ, Zhang L, Zou Y, Chen YM, Geng Z, Zhou JF, Wang JM, Liu X, Wang JX, Yuan WP,Huang G*, Cheng T* and Wang QF*. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nature Genetics. 46(3):287-293,2014 

7. Zhou J, Wu J, Li B, Liu D, Yu J, Yan XM, Zheng S, Wang JG, Zhang LX, Zhang L, He FH, Li Q, Chen AL, Zhang Y, Zhao XH, Guan YH, Zhao XH, Yan J, Ni J, Nobrega M, Löwenberg B, Delwel R, Valk P J, Kumar A, Xie L, Tenen DG, Huang G* and Wang QF*. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia. 28(7):1436-1448,2014 

8. Wang QF*, Li YJ, Dong JF, Li B, KaberleinJJ, Zhang L, Arimura FE, Luo RT, Ni J, He FH, Wu J,Mattison R, Zhou J, Wang CZ, Prabhakar S, Nobrega M A and Thirman M J*.Regulation of MEIS1 by distal enhancer elements in acute leukemia.Leukemia.28:138-146,2014  

9. Wang QF, Wu G, Mi SL, He FH, Wu J, Dong JF, Luo RT, Mattison R, Kaberlein JJ, Prabhakar S, Ji HK and Thirman MJ. MLL fusion proteins preferentially regulate a subset of wild type MLL target genes in the leukemic genome. Blood.117(25):6895-6905,2011

10. Xing C*, Wang QF*, Li B, Tian H, Ni Y, Yin S and Li G. Methylation and expression analysis of tumor suppressor genes p15 and p16 in benzene poisoning. Chemico-Biological Interactions. 184:306-309,2010

11. Wang QF*, Prabhakar S, Chanan S, Cheng JF, Rubin EM and Boffelli D*. Detection of weakly conserved ancestral mammalian regulatory sequences by primate comparisons. Genome Biology. 8(1):R1,2007 

12. Wang QF§, Prabhakar S§, Wang Q, Moses A, Chanan S, Brown M, Eisen M, Cheng JF, Rubin E and Boffelli D. Primate-specific evolution of an LDLR enhancer. Genome Biology.7(8):R68, 2006 

13. Wang QF, Liu X, O’nell J, Peng Z, Krauss R, Rainwater DL, Vandeberg JL, Rubin EM, Cheng J F and Pennacchio LA. Haplotypes in the APOA1-C3-A4-A5 Gene Cluster affect Plasma Lipids in both Humans and Baboons. Human Molecular Genetics.13(10):1049-1056,2004 

14. Wang QF, Cleaves R, Kummalue T, Nerlov C and Friedman A D. Cell cycle inhibition mediated by the outer surface of the C/EBPalpha basic region is required but not sufficient for granulopoiesis. Oncogene. 22(17):2548-2557,2003 

15. Wang QF and Friedman A D. C/EBPs are required for granulopoiesis independent of their induction of the granulocyte-colony stimulating factor receptor.Blood. 99(8):2776-2785,2002

16. Wang QF, Lauring J, and Schlissel M S. c-Myb binds to a sequence in the proximal region of the RAG-2 promoter and is essential for promoter activity in T-lineage cells.Molecular and Cellular Biology.20:9203-9211,2000 


Cheng Tao, Wang Qianfei, Zhu Xiaofan, Yuan Weiping, Assay kit for detecting stimulated emission depletion 2 (STED 2), 2015.3.11, China, ZL 201310107889.9

Research Interests

1) Explore the functional and clinical relevance of newly discovered genomic aberrations in acute leukemia; 2) identify key genes/pathways critical for drug resistance in chemotherapy; 3) define genomic signatures for the classification of responders in AML drug treatment.


1.The Role of Histone Modifications in AML and Leukemic Stem Cell Function. 2014 International Forum on Stem Cells, Tianjin, China, November 3rd, 2014.

2. The Genome and Transcriptome of MLL Leukemia: Biological Insights Beyond the Fusion Pathway. 2014 Tenth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Cincinnati, OH, USA, May 5th, 2014.

3.Whole-Genome Sequencing of a Monozygotic Twin Pair Reveals Functional Cooperative Mutations of SETD2 in Acute Leukemia. American Society of Hematology Annual Meeting, Atlanta, GA, December 9th, 2012.

4.Transcriptional Network Mapping Reveals PU.1 as an Essential Positive Regulator in MLL fusion Leukemias. 2012 International Forum on Stem Cells, Tianjin, China, November 3rd, 2012.

5. Essential Role for PU.1 in MEIS1 Activation and MLL fusion Leukemia.  2011 Workshop on Myeloid Development,  San Diego, California, December 9th, 2011.

6. MLL Translocation: Epigenetic Landscapes in the Development of Acute Leukemia. The 6th Congress of Asian Society for Pediatric Research, Taipei, Taiwan, April 16th, 2010.



Institute of Hematology, Chinese Academy of Medical Sciences 

​Tongji Hospital of Huazhong University of Science and Technology 

Cincinnati Children's Hospital Medical Center

The Johns Hopkins University


Graduate Students:


YANG Xuejing (Experimental biology)


ZHAN Di (Experimental biology)

BU Jiachen (Experimental biology)


JIN Chen(Experimental biology)


XU Zehui (Bioinformatics)

DOAA KHALED A ALAMOUDI (Experimental biology)


YANG Jingyi (Experimental biology)

SUN Shu (Experimental biology)


ZHANG Ya (Experimental biology)

CHEN Lei (Experimental biology)

Honors & Distinctions

2008 Cancer Research Foundation Young Investigator Award

2014 The National Science Fund for Distinguished Young Scholars

2015 Zhu Liyuehua Excellent Teacher Award

2015 National Hundred, Thousand and Ten Thousand Talents Project